Melbourne biotech Magellan Stem Cells is 17 years old and about to begin a pivotal Phase 3 trial of its stem cell treatment for osteoarthritis, a condition affecting more than 2 million Australians. Yet under legislation now before the Federal Parliament, it may also lose access to the refundable R&D Tax Incentive.
Biotech sector warns R&D tax changes could drive clinical trials offshore
October 28, 2026 Latest NewsAustralian Biotech
Latest Video
New Stories
-
Government turns again to cheaper medicines as Guild eyes co-payment freeze
November 19, 2026 - - Latest News -
New Zealand risks losing $763 million clinical trials sector as other countries step up
November 19, 2026 - -
A tale of two government programs - one held flat and the other still running hot
November 19, 2026 - - Latest News -
Moderna's mRNA flu vaccines and a GLP-1 review headline March PBAC agenda
November 19, 2026 - - Latest News -
Immutep goes back to smaller batch efti after review finds glycan differences in failed trial drug
November 18, 2026 - - Australian Biotech -
Genetic Signatures walks away from Microba merger after funding shortfall
November 18, 2026 - - Australian Biotech -
Hungary's Gedeon Richter offers $604 million for Mayne Pharma
November 18, 2026 - - Latest News

